Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production.
## Primary Indications
* Gastroesophageal reflux disease (GERD) - erosive esophagitis healing and symptom relief
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
* Duoenocytosis and gastric ulcer treatment and maintenance
* H. pylori eradication (in combination regimens)
## Adult Dosing
* **GERD (erosive esophagitis):** 40 mg orally or intravenously once daily for 4 to 8 weeks.
* **GERD (maintenance):** 20 mg to 40 mg orally once daily.
* **Duoenocytosis and Gastric Ulcers:** 40 mg orally or intravenously once daily for 4 to 8 weeks.
* **Pathological Hypersecretory Conditions:** Starting dose 40 mg orally or intravenously twice daily. Doses may be increased as needed. Maximum recommended daily dose is 240 mg.
* **H. pylori Eradication:** 40 mg orally twice daily for 7 to 14 days, in combination with antibiotics (e.g., amoxicillin and clarithromycin or metronidazole and clarithromycin).
## Pediatric Dosing
Dosing for pediatric patients is weight-based and depends on the indication. Consult specific pediatric guidelines or product labeling for precise recommendations. For example:
* **GERD (ages 5 to 11 years):** 20 mg to 40 mg orally once daily.
* **GERD (ages 12 to 17 years):** 40 mg orally once daily for healing of erosive esophagitis; 20 mg to 40 mg orally once daily for maintenance.
## Dose Adjustments
* **Hepatic Impairment:** Maximum dose of 20 mg orally once daily.
* **Renal Impairment:** No dose adjustment is typically required.
## Contraindications
* Known hypersensitivity to pantoprazole or other benzimidazole derivatives.
## Adverse Effects
Common: Headache, diarrhea, nausea, abdominal pain, flatulence, dizziness.
Less Common: Rash, pruritus, elevated liver enzymes, myalgia.
Serious: Clostridium difficile-associated diarrhea, bone fractures (hip, wrist, spine) with long-term use, hypomagnesemia, vitamin B12 deficiency, fundic gland polyps.
## Key Drug Interactions
* **Drugs dependent on gastric pH for absorption:** May decrease absorption of ketoconazole, itraconazole, posaconazole, iron salts, and cyanocobalamin.
* **Methotrexate:** PPIs may increase serum levels of methotrexate, potentially leading to toxicity.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. May affect metabolism of drugs like clopidogrel (though clinical significance is debated).
## Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., tremor, tetany, seizures).
* Consider monitoring magnesium levels in patients on long-term therapy or concomitant medications that may cause hypomagnesemia.
* Monitor for bone fracture risk with long-term use.
* Monitor for signs of vitamin B12 deficiency with long-term use.
* Monitor for C. difficile infection if diarrhea occurs.
## Clinical Pearls
* Administer oral pantoprazole 30 minutes before a meal.
* For intravenous administration, reconstitute and further dilute as per manufacturer instructions.
* Long-term use of PPIs is associated with increased risk of fractures, C. difficile infection, and potential nutrient deficiencies. Use the lowest effective dose for the shortest duration necessary.
* If a patient is on concomitant therapy that is dependent on gastric pH for absorption, monitor for efficacy and consider alternative agents if necessary.
***
*This information is intended for healthcare professionals. Please consult the official prescribing information and relevant clinical guidelines for complete details and to ensure patient safety.*
